Chemical and biological features of Burkholderia cepacia complex lipopolysaccharides

Innate Immunity

Volumn 14, Issue 3, 2008, Pages 127-144

  De Soyza, Anthony ^a   Silipo, Alba ^b   Lanzetta, Rosa ^b   Govan, R John ^c   Molinaro, Antonio ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Burkholderia cenocepacia; Cystic fibrosis; Lipopolysaccharide; Pseudomonas aeruginosa; Virulence

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYCLIC AMP; DEFENSIN; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; LIPOPOLYSACCHARIDE;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BURKHOLDERIA CEPACIA COMPLEX; CHEMICAL STRUCTURE; CROSS REACTION; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GRAM NEGATIVE INFECTION; HUMAN; IMMUNE RESPONSE; LUNG TRANSPLANTATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; REVIEW; ANIMAL; BURKHOLDERIA INFECTION; CHEMISTRY; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PATHOGENICITY; SIGNAL TRANSDUCTION;

BURKHOLDERIA; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA COMPLEX; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

ANIMALS; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA INFECTIONS; DEFENSINS; DRUG RESISTANCE, BACTERIAL; HUMANS; LIPOPOLYSACCHARIDES; SIGNAL TRANSDUCTION;

EID: 58149107409     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425908093984     Document Type: Review

References (121)

1. Govan JR, Hughes JE, Vandamme P. Burkholderia cepacia: Medical, taxonomic and ecological issues. J Med Microbiol 1996; 45: 395-407.
2. Mahenthiralingam E., Vandamme P. Taxonomy and pathogenesis of the Burkholderia cepacia complex. Chron Respir Dis 2005; 2: 209-217.
3. Mahenthiralingam E., Urban TA, Goldberg JB The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 2005; 3: 144-156.
4. Jones AM, Dodd ME, Webb AK Burkholderia cepacia: Current clinical issues, environmental controversies and ethical dilemmas. Eur Respir J 2001; 17: 295-301.
5. Isles A., Maclusky I., Corey M. et al. Pseudomonas cepacia infection in cystic fibrosis: An emerging problem. J Pediatr 1984; 104: 206-210.
6. Holmes A., Govan J., Goldstein R. Agricultural use of Burkholderia (Pseudomonas) cepacia: A threat to human health? Emerg Infect Dis 1998; 4: 221-227.
7. Yabuuchi E., Kosako Y., Oyaizu H. et al. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol 1992; 36: 1251-1275.
8. Vandamme P., Holmes B., Vancanneyt M. et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 1997; 47: 1188-1200.
9. Vandamme P., Henry D., Coenye T. et al. Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. FEMS Immunol Med Microbiol 2002; 33: 143-149.
10. Vermis K., Coenye T., Mahenthiralingam E., Nelis HJ, Vandamme P. Evaluation of species-specific recA-based PCR tests for genomovar level identification within the Burkholderia cepacia complex. J Med Microbiol 2002; 51: 937-940.
11. Mahenthiralingam E., Coenye T., Chung JW et al. Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol 2000; 38: 910-913.
12. + Pseudomonas (Burkholderia) cepacia causing cystic fibrosis centre epidemics in North America and Britain. Nat Med 1995; 1: 661-666.
13. Clode FE, Kaufmann ME, Malnick H., Pitt TL Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom. J Clin Microbiol 2000; 38: 1763-1766.
14. Baldwin A., Mahenthiralingam E., Drevinek P. et al. Elucidating the global epidemiology of Burkholderia multivorans in cystic fibrosis by multilocus sequence typing. J Clin Microbiol 2008; 46: 290-295.
15. Balandreau J., Viallard V., Cournoyer B., Coenye T., Laevens S., Vandamme P. Burkholderia cepacia genomovar III is a common plant-associated bacterium. Appl Environ Microbiol 2001; 67: 982-985.
16. LiPuma JJ, Spilker T., Coenye T., Gonzalez cystic fibrosis. An epidemic Burkholderia cepacia complex strain identified in soil. Lancet 2002; 359: 2002-2003.
17. Frangolias DD, Mahenthiralingam E., Rae S. et al. Burkholderia cepacia in cystic fibrosis. Variable disease course. Am J Respir Crit Care Med 1999; 160: 1572-1577.
18. Soni R., Marks G., Henry DA et al. Effect of Burkholderia cepacia infection in the clinical course of patients with cystic fibrosis: A pilot study in a Sydney clinic. Respirology 2002; 7: 241-245.
19. Baldwin A., Mahenthiralingam E., Drevinek P. et al. Environmental Burkholderia cepacia complex isolates in human infections. Emerg Infect Dis 2007; 13: 458-461.
20. LiPuma JJ, Spilker T., Gill LH, Campbell 3rd PW, Liu L., Mahenthiralingam E. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 2001; 164: 92-96.
21. Speert DP, Henry D., Vandamme P., Corey M., Mahenthiralingam E. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis 2002; 8: 181-187.
22. Govan JR, Brown AR, Jones AM Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol 2007; 2: 153-164.
23. Chen JS, Witzmann KA, Spilker T., Fink RJ, LiPuma JJ Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 2001; 139: 643-649.
24. Coenye T., Spilker T., Van Schoor A., LiPuma JJ, Vandamme P. Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe. Thorax 2004; 59: 952-954.
25. Mahenthiralingam E., Simpson DA, Speert DP Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol 1997; 35: 808-816.
26. Baldwin A., Sokol PA, Parkhill J., Mahenthiralingam E. The Burkholderia cepacia epidemic strain marker is part of a novel genomic island encoding both virulence and metabolism-associated genes in Burkholderia cenocepacia. Infect Immun 2004; 72: 1537-1547.
27. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998; 351: 24-27.
28. Husain S., Singh N. Burkholderia cepacia infection and lung transplantation. Semin Respir Infect 2002; 17: 284-290.
29. de Perrot M., Chaparro C., McRae K. et al. Twenty-year experience of lung transplantation at a single center: Influence of recipient diagnosis on long-term survival. J Thorac Cardiovasc Surg 2004; 127: 1493-1501.
30. Chaparro C., Maurer J., Gutierrez C. et al. Infection with Burkholderia cepacia in cystic fibrosis; outcome following lung transplantation. Am J Respir Crit Care Med 2001; 163: 43-48.
31. Mariencheck Jr WI, Palmer SM, Tapson VF, Davis RD Survival following lung transplantation of Cystic Fibrosis patients colonized with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161: 720.
32. De Soyza A., McDowell A., Archer L. et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 2001; 358: 1780-1781.
33. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164: 2102-2106.
34. De Soyza A., Morris K., McDowell A. et al. Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation. Thorax 2004; 59: 526-528.
35. Alexander BD, Petzold EW, Reller LB et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8: 1025-1030.
36. Boussaud V., Guillemain R., Grenet D. et al. Clinical outcome following lung transplantation in cystic fibrosis patients colonized with Burkholderia cepacia complex: Results from two French centers. Thorax 2008; epub.
37. Smith EE, Buckley DG, Wu Z. et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006; 103: 8487-8492.
38. Jones AM, Dodd ME, Govan JR et al. Burkholderia cenocepacia and Burkholderia multivorans: Influence on survival in cystic fibrosis. Thorax 2004; 59: 948-951.
39. Ledson MJ, Gallagher MJ, Corkill JE, Hart CA, Walshaw MJ Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia. Thorax 1998; 53: 432-436.
40. Blackburn L., Brownlee K., Conway S., Denton M. 'Cepacia syndrome' with Burkholderia multivorans, 9 years after initial colonization. J Cyst Fibros 2004; 3: 133-134.
41. Mahenthiralingam E., Vandamme P., Campbell ME et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: Virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001; 33: 1469-1475.
42. Vandamme P., Holmes B., Coenye T. et al. Burkholderia cenocepacia sp. nov. - a new twist to an old story. Res Microbiol 2003; 154: 91-96.
43. Coenye T., LiPuma JJ Population structure analysis of Burkholderia cepacia genomovar III: Varying degrees of genetic recombination characterize major clonal complexes. Microbiology 2003; 149: 77-88.
44. Bernier SP, Sokol PA Use of suppression-subtractive hybridization to identify genes in the Burkholderia cepacia complex that are unique to Burkholderia cenocepacia. J Bacteriol 2005; 187: 5278-5291.
45. Sajjan U., Wu Y., Kent G., Forstner J. Preferential adherence of cable-piliated Burkholderia cepacia to respiratory epithelia of cystic fibrosis knockout mice and human cystic fibrosis lung explants. J Med Microbiol 2000; 49: 875-885.
46. Sajjan US, Corey M., Karmali MA, Forstner JF Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest 1992; 89: 648-656.
47. Sajjan U., Corey M., Humar A. et al. Immunolocalisation of Burkholderia cepacia in the lungs of cystic fibrosis patients. J Med Microbiol 2001; 50: 535-546.
48. Mohr CD, Tomich M., Herfst CA Cellular aspects of Burkholderia cepacia infection. Microbes Infect Institut Pasteur 2001; 3: 425-435.
49. Schwab U., Leigh M., Ribeiro C. et al. Patterns of epithelial cell invasion by different species of the Burkholderia cepacia complex in well-differentiated human airway epithelia. Infect Immun 2002; 70: 4547-4555.
50. Savoia D., Zucca M. Clinical and environmental Burkholderia strains: biofilm production and intracellular survival. Curr Microbiol 2007; 54: 440-444.
51. Tomich M., Herfst CA, Golden JW, Mohr CD Role of flagella in host cell invasion by Burkholderia cepacia. Infect Immun 2002; 70: 1799-1806.
52. Urban TA, Griffith A., Torok AM, Smolkin ME, Burns JL, Goldberg JB Contribution of Burkholderia cenocepacia flagella to infectivity and inflammation. Infect Immun 2004; 72: 5126-5134.
53. Chung JW, Speert DP Proteomic identification and characterization of bacterial factors associated with Burkholderia cenocepacia survival in a murine host. Microbiology 2007; 153: 206-214.
54. Lefebre M., Valvano M. In vitro resistance of Burkholderia cepacia complex isolates to reactive oxygen species in relation to catalase and superoxide dismutase production. Microbiology 2001; 147: 97-109.
55. Trepanier S., Prince A., Huletsky A. Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother 1997; 41: 2399-2405.
56. Crowley D., Daly M., Lucey B. et al. Molecular epidemiology of cystic fibrosis-linked Burkholderia cepacia complex isolates from three national referral centres in Ireland. J Appl Microbiol 2002; 92: 992-1004.
57. Burns JL, Wadsworth CD, Barry JJ, Goodall CP Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob Agents Chemother 1996; 40: 307-313.
58. Chung JW, Altman E., Beveridge TJ, Speert DP Colonial morphology of Burkholderia cepacia complex genomovar III: Implications in exopolysaccharide production, pilus expression, and persistence in the mouse. Infect Immun 2003; 71: 904-909.
59. Middleton B., Rodgers HC, Camara M., Knox AJ, Williams P., Hardman A. Direct detection of N-acylhomoserine lactones in cystic fibrosis sputum. FEMS Microbiol Lett 2002; 207: 1-7.
60. Chambers CE, Visser MB, Schwab U., Sokol PA Identification of N-acylhomoserine lactones in mucopurulent respiratory secretions from cystic fibrosis patients. FEMS Microbiol Lett 2005; 244: 297-304.
61. Riedel K., Hentzer M., Geisenberger O. et al. N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology 2001; 147: 3249-3262.
62. Huber B., Riedel K., Hentzer M. et al. The cep quorum-sensing system of Burkholderia cepacia H111 controls biofilm formation and swarming motility. Microbiology 2001; 147: 2517-2528.
63. Conway BA, Greenberg EP Quorum-sensing signals and quorum-sensing genes in Burkholderia vietnamiensis. J Bacteriol 2002; 184: 1187-1191.
64. Lutter E., Lewenza S., Dennis JJ, Visser MB, Sokol PA Distribution of quorum-sensing genes in the Burkholderia cepacia complex. Infect Immun 2001; 69: 4661-4666.
65. Malott RJ, Baldwin A., Mahenthiralingam E., Sokol PA Characterization of the cciIR quorum-sensing system in Burkholderia cenocepacia. Infect Immun 2005; 73: 4982-4992.
66. Kothe M., Antl M., Huber B. et al. Killing of Caenorhabditis elegans by Burkholderia cepacia is controlled by the cep quorum-sensing system. Cell Microbiol 2003; 5: 343-351.
67. Lewenza S., Sokol PA Regulation of ornibactin biosynthesis and N-acyl-L-homoserine lactone production by CepR in Burkholderia cepacia. J Bacteriol 2001; 183: 2212-2218.
68. Yang H., Matewish M., Loubens I., Storey DG, Lam JS, Jin S. migA, a quorum-responsive gene of Pseudomonas aeruginosa, is highly expressed in the cystic fibrosis lung environment and modifies low-molecular-mass lipopolysaccharide. Microbiology 2000; 146: 2509-2519.
69. Riedel K., Arevalo-Ferro C., Reil G., Gorg A., Lottspeich F., Eberl L. Analysis of the quorum-sensing regulon of the opportunistic pathogen Burkholderia cepacia H111 by proteomics. Electrophoresis 2003; 24: 740-750.
70. Moura JA, Cristina de Assis M., Ventura GC et al. Differential interaction of bacterial species from the Burkholderia cepacia complex with human airway epithelial cells. Microbes Infect Institut Pasteur 2008; 10: 52-59.
71. Straus DC, Lonon MK, Woods DE, Garner CW Production of an extracellular toxic complex by various strains of Pseudomonas cepacia. J Med Microbiol 1989; 30: 17-22.
72. Straus DC, Woods DE, Lonon MK, Garner CW The importance of extracellular antigens in Pseudomonas cepacia infections. J Med Microbiol 1988; 26: 269-280.
73. Straus DC, Lonon MK, Woods DE, Garner CW 3-deoxy-D-manno-2-octulosonic acid in the lipopolysaccharide of various strains of Pseudomonas cepacia. J Med Microbiol 1990; 33: 265-269.
74. Shaw D., Poxton IR, Govan JR Biological activity of Burkholderia (Pseudomonas) cepacia lipopolysaccharide. FEMS Immunol Med Microbiol 1995; 11: 99-106.
75. Zughaier SM, Ryley HC, Jackson SK Lipopolysaccharide (LPS) from Burkholderia cepacia is more active than LPS from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in stimulating tumor necrosis factor alpha from human monocytes. Infect Immun 1999; 67: 1505-1507.
76. Palfreyman RW, Watson ML, Eden C., Smith AW Induction of biologically active interleukin-8 from lung epithelial cells by Burkholderia (Pseudomonas) cepacia products. Infect Immun 1997; 65: 617-622.
77. Pitt TL, Kaufmann ME, Patel PS, Benge LC, Gaskin S., Livermore DM Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol 1996; 44: 203-210.
78. Simpson IN, Finlay J., Winstanley DJ et al. Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis. J Antimicrob Chemother 1994; 34: 353-361.
79. Rabkin CS, Jarvis WR, Anderson RL et al. Pseudomonas cepacia typing systems: Collaborative study to assess their potential in epidemiologic investigations. Rev Infect Dis 1989; 11: 600-607.
80. Manniello JM, Heymann H., Adair FW Resistance of spheroplasts and whole cells of Pseudomonas cepacia to polymyxin B. Antimicrob Agents Chemother 1978; 14: 500-504.
81. Nelson JW, Barclay GR, Micklem LR, Poxton IR, Govan JR Production and characterisation of mouse monoclonal antibodies reactive with the lipopolysaccharide core of Pseudomonas aeruginosa. J Med Microbiol 1992; 36: 358-365.
82. Manniello JM, Heymann H., Adair FW Isolation of atypical lipopolysaccharides from purified cell walls of Pseudomonas cepacia. J Gen Microbiol 1979; 112: 397-400.
83. Cox AD, Wilkinson SG Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance. Mol Microbiol 1991; 5: 641-646.
84. Hughes JE, Stewart J., Barclay GR, Govan JR Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Infect Immun 1997; 65: 4281-4287.
85. Shimomura H., Matsuura M., Saito S., Hirai Y., Isshiki Y., Kawahara K. Lipopolysaccharide of Burkholderia cepacia and its unique character to stimulate murine macrophages with relative lack of interleukin-1beta-inducing ability. Infect Immun 2001; 69: 3663-3669.
86. Gronow S., Noah C., Blumenthal A., Lindner B., Brade H. Construction of a deep-rough mutant of Burkholderia cepacia ATCC 25416 and characterization of its chemical and biological properties. J Biol Chem 2003; 278: 1647-1655.
87. De Soyza A., Ellis CD, Anjam CMA, Corris PA, DeMarco De Hormaeche R. Burkholderia cenocepacia lipopolysaccharide, lipid A and proinflammatory activity. Am J Respir Crit Care Med 2004; 170: 70-77.
88. Lacy DE, Smith AW, Stableforth DE, Smith G., Weller PH, Brown MR Serum IgG response to Burkholderia cepacia outer membrane antigens in cystic fibrosis: Assessment of cross-reactivity with Pseudomonas aeruginosa. FEMS Immunol Med Microbiol 1995; 10: 253-261.
89. Nelson JW, Butler SL, Brown PH, Greening AP, Govan JR Serum IgG and sputum IgA antibody to core lipopolysaccharide antigen from Pseudomonas cepacia in patients with cystic fibrosis. J Med Microbiol 1993; 39: 39-47.
90. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002; 71: 635-700.
91. Whitfield C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem 2006; 75: 39-68.
92. Meredith TC, Mamat U., Kaczynski Z., Lindner B., Holst O., Woodard RW Modification of lipopolysaccharide with colanic acid (M-antigen) repeats in Escherichia coli. J Biol Chem 2007; 282: 7790-7798.
93. Vinion-Dubiel AD, Goldberg JB Lipopolysaccharide of Burkholderia cepacia complex. J Endotoxin Res 2003; 9: 201-213.
94. Evans E., Poxton IR, Govan JR Lipopolysaccharide chemotypes of Burkholderia cepacia. J Med Microbiol 1999; 48: 825-832.
95. Kenna DT, Barcus VA, Langley RJ, Vandamme P., Govan JR Lack of correlation between O-serotype, bacteriophage susceptibility and genomovar status in the Burkholderia cepacia complex. FEMS Immunol Med Microbiol 2003; 35: 87-92.
96. Iihara H., Niwa T., Shah MM et al. Rapid multiplex immunofluorescent assay to detect antibodies against Burkholderia pseudomallei and taxonomically closely related nonfermenters. Jpn J Infect Dis 2007; 60: 230-234.
97. Albrecht MT, Wang W., Shamova O., Lehrer RI, Schiller NL Binding of protegrin-1 to Pseudomonas aeruginosa and Burkholderia cepacia. Respir Res 2002; 3: 18.
98. Silipo A., Molinaro A., Cescutti P. et al. Complete structural characterization of the lipid A fraction of a clinical strain of B. cepacia genomovar I lipopolysaccharide. Glycobiology 2005; 15: 561-570.
99. Molinaro A., Lindner B., De Castro C. et al. The structure of lipid A of the lipopolysaccharide from Burkholderia caryophylli with a 4-amino-4-deoxy-L-arabinopyranose 1-phosphate residue exclusively in glycosidic linkage. Chemistry 2003; 9: 1542-1548.
100. Silipo A., Molinaro A., Ierano T. et al. The complete structure and pro-inflammatory activity of the lipooligosaccharide of the highly epidemic and virulent Gram-negative bacterium Burkholderia cenocepacia ET-12 (strain J2315). Chemistry 2007; 13: 3501-3511.
101. Krejci E., Kroppenstedt RM Differentiation of species combined into the Burkholderia cepacia complex and related taxa on the basis of their fatty acid patterns. J Clin Microbiol 2006; 44: 1159-1164.
102. Silipo A., Molinaro A., Comegna D. et al. Full structural characterisation of the lipooligosaccharide of a Burkholderia pyrrocinia clinical isolate. Eur J Org Chem 2006; 21: 4874-4883.
103. Ortega XP, Cardona ST, Brown AR et al. A putative gene cluster for aminoarabinose biosynthesis is essential for Burkholderia cenocepacia viability. J Bacteriol 2007; 189: 3639-3644.
104. Reife RA, Coats SR, Al- Qutub M. et al. Porphyromonas gingivalis lipopolysaccharide lipid A heterogeneity: Differential activities of tetra- and penta-acylated lipid A structures on E-selectin expression and TLR4 recognition. Cell Microbiol 2006; 8: 857-868.
105. Munford RS Detoxifying endotoxin: Time, place and person. J Endotoxin Res 2005; 11: 69-84.
106. Isshiki Y., Zahringer U., Kawahara K. Structure of the core-oligosaccharide with a characteristic D-glycero-alpha-D-talo-oct- 2-ulosylonate-(2→4)-3-deoxy-D-manno-oct-2-ulosonate [alpha-Ko-(2→4)-Kdo] disaccharide in the lippopolysaccharide from Burkholderia cepacia. Carbohydr Res 2003; 338: 2659-2666.
107. Loutet SA, Flannagan RS, Kooi C., Sokol PA, Valvano MA A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo. J Bacteriol 2006; 188: 2073-2080.
108. Butler SL, Nelson JW, Poxton IR, Govan JR Serum sensitivity of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis. FEMS Immunol Med Microbiol 1994; 8: 285-292.
109. Brade L., Gronow S., Wimmer N., Kosma P., Brade H. Monoclonal antibodies against 3-deoxy-alpha-D-manno-oct-2-ulosonic acid (Kdo) and D-glycero-alpha-D-talo-oct-2-ulosonic acid (Ko). J Endotoxin Res 2002; 8: 357-356.
110. Leone S., Molinaro A., Gerber IB, Dubery IA, Lanzetta R., Parrilli M. The O-chain structure from the LPS of the endophytic bacterium Burkholderia cepacia strain ASP B 2D. Carbohydr Res 2006; 341: 2954-2958.
111. Faure R., Shiao TC, Lagnoux D., Giguere D., Roy R. En route to a carbohydrate-based vaccine against Burkholderia cepacia. Org Biomol Chem 2007; 5: 2704-2708.
112. Bamford S., Ryley H., Jackson SK Highly purified lipopolysaccharides from Burkholderia cepacia complex clinical isolates induce inflammatory cytokine responses via TLR4-mediated MAPK signalling pathways and activation of NFkappaB. Cell Microbiol 2007; 9: 532-543.
113. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol 2002; 3: 354-359.
114. Shimomura H., Matsuura M., Saito S., Hirai Y., Isshiki Y., Kawahara K. Unusual interaction of a lipopolysaccharide isolated from Burkholderia cepacia with polymyxin B. Infect Immun 2003; 71: 5225-5230.
115. Bernier SP, Silo-Suh L., Woods DE, Ohman DE, Sokol PA Comparative analysis of plant and animal models for characterization of Burkholderia cepacia virulence. Infect Immun 2003; 71: 5306-5313.
116. Flannagan RS, Aubert D., Kooi C., Sokol PA, Valvano MA Burkholderia cenocepacia requires a periplasmic HtrA protease for growth under thermal and osmotic stress and for survival in vivo. Infect Immun 2007; 75: 1679-1689.
117. Ernst RK, Guina T., Miller SI Salmonella typhimurium outer membrane remodeling: Role in resistance to host innate immunity. Microbes Infect Institut Pasteur 2001; 3: 1327-1334.
118. McPhee JB, Lewenza S., Hancock RE Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol 2003; 50: 205-217.
119. Kawasaki K., Ernst RK, Miller SI Deacylation and palmitoylation of lipid A by Salmonellae outer membrane enzymes modulate host signaling through Toll-like receptor 4. J Endotoxin Res 2004; 10: 439-444.
120. Kawasaki K., Ernst RK, Miller SI 3-O-deacylation of lipid A by PagL, a PhoP/PhoQ-regulated deacylase of Salmonella typhimurium, modulates signaling through Toll-like receptor 4. J Biol Chem 2004; 279: 20044-20048.
121. Ernst RK, Yi EC, Guo L. et al. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 1999; 286: 1561-1565.